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Abstract
Background: Approximately one third of all patients with CRC present with, or subsequently develop, colorectal
liver metastases (CRLM). The objective of this population-based analysis was to assess the impact of resection of
liver only, lung only and liver and lung metastases on survival in patients with metastatic colorectal cancer (mCRC)
and resected primary tumor.
Methods: Ten thousand three hundred twenty-five patients diagnosed with mCRC between 2010 and 2015 with
resected primary were identified in the Surveillance, Epidemiology and End Results (SEER) database. Overall, (OS)
and cancer-specific survival (CSS) were analyzed by Cox regression with multivariable, inverse propensity weight,
near far matching and propensity score adjustment.
Results: The majority (79.4%) of patients had only liver metastases, 7.8% only lung metastases and 12.8% metastases of
lung and liver. 3-year OS was 44.5 and 27.5% for patients with and without metastasectomy (HR = 0.62, 95% CI: 0.58–
0.65, P < 0.001). Metastasectomy uniformly improved CSS in patients with liver metastases (HR = 0.72, 95% CI: 0.67–0.77,
P < 0.001) but not in patients with lung metastases (HR = 0.84, 95% CI: 0.62–1.12, P = 0.232) and combined liver and
lung metastases (HR = 0.89, 95% CI: 0.75–1.06, P = 0.196) in multivariable analysis. Adjustment by inverse propensity
weight, near far matching and propensity score and analysis of OS yielded similar results.
Conclusions: This is the first SEER analysis assessing the impact of metastasectomy in mCRC patients with removed
primary tumor on survival. The analysis provides compelling evidence of a statistically significant and clinically
relevant increase in OS and CSS for liver resection but not for metastasectomy of lung or both sites.
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Background
Colorectal cancer (CRC) is one of the most frequent ma-
lignant tumors. Indeed, based on the latest update of the
national cancer statistics at the United States, CRC has
the third highest incidence in both men and in women
[1]. The incidence rate is estimated to be 1.2 million per
annum in the US, and more than 600,000 patients die
from this cancer every year [2]. Approximately one third
of all patients with CRC present with, or subsequently
develop, colorectal liver metastases (CRLM). Moreover,
another 23–38% of patients already have, or will develop
extra-hepatic disease [3–5].
Over the past years the landscape of treatment modal-
ities in patients with metastatic colorectal cancer has ex-
panded tremendously and improved the median overall
survival (OS) from a median of 5 months in 1993 [6] to
more than 3 years nowadays [7]. Factors improving
median survival rates of metastatic CRC are a better
understanding of the heterogeneity of the disease based
on rat sarcoma (RAS) and rapidly accelerated fibrosar-
coma- (RAF) mutations as well as mismatch repair
status, which allows a more patient-tailored treatment
using antibody treatment in combination with chemo-
therapy or immunotherapy [8–12]. Moreover, the loca-
tion of the primary cancer – left versus right hemicolon
– has been recognized as important prognostic and
predictive factor, particularly regarding the efficacy of
epidermal growth factor receptor (EGFR) antibodies
[13–16]. Despite this, rapidly accumulating knowledge
about tumor heterogeneity of metastatic colorectal can-
cer (mCRC), many relevant questions regarding treat-
ment sequences as well the impact and timing of
resection of lung and liver metastases remain. The latest
versions of national and international guidelines include
resection of metastases at some point in the treatment
of mCRC. However, these recommendations are often
vague [17, 18]. While it is well recognized that liver re-
sections in curative intent should be performed, there is
ongoing debate regarding the resection of lung metasta-
ses and both lung and liver metastases.
Hence, the objective of the present population-
based analysis was to assess the impact of resection
of liver only, lung only and liver and lung metastases




The 2015 custom text data-version of the Surveillance,
Epidemiology, and End Results (SEER) Program of the
National Cancer Institute in the United States, cover-
ing approximately 28% of cancer cases in the United
States, was the source of the present population-based
analysis [19].
Study design
All patients diagnosed with colorectal cancer between
2010 and 2015 were eligible for the analysis. Patients
aged below 18 years, with missing diagnosis by histology,
secondary malignancies preceding the mCRC, other hist-
ology than adenocarcinoma, incomplete staging, non-
metastatic cancer, overlapping or unknown localization
of the primary, metastasis other than liver and/or lung,
undefined localization of the metastasis, not-resected
primary, and unknown non − primary surgery or non −
primary surgery limited to distant lymph nodes were
excluded. Figure 1 depicts the selection process.
Statistical methods
Statistical analyses were performed using the R statistical
software (www.r-project.org). A two-sided p-value < 0.05
was considered statistically significant. Cancer-specific
(CSS) and overall survivals were the co-primary end-
points. P-values were estimated using likelihood-ratio
tests. The proportional hazard assumption for Cox re-
gression was tested by scaled Schoenfeld residuals and
by inspection of the hazard ratio (HR) plots [20]. After
descriptive analysis, the imbalances regarding prognostic
factors between patients with and without metastasect-
omy were assessed by multivariable logistic regression
with adjustment for the site of the primary, metastatic
site (lung, liver, both), T-stage, nodal status, grading,
chemotherapy [21], year of diagnosis, age, gender, ethni-
city, and marital status (risk set). The impact of metasta-
sectomy on survival was analyzed with and without
adjustment for the risk set. The impact of metastasect-
omy on survival was further analyzed with inverse pro-
pensity weight adjustment (stabilized weights) using the
“ipw” R package [22]. Thereafter an exact matched pro-
pensity score and weighted analysis was performed as a
superior and more refined statistical method for adjust-
ment [23–25] using the “MatchIt” R package [26]. Each
patient with metastasectomy was matched to all possible
patients without with exactly the same values on all the
covariates in the risk set, forming subclasses such that
within each subclass both weighted groups have exactly
the same covariate values. Patients without a counterpart
among the patients in the other group were excluded
from this analysis. Finally, a near-far matched analysis
was performed to assess the impact of metastasectomy
with adjustment for unobserved confounding variables.
FIPS county codes were used as the instrumental vari-
able to build an encouraged and discouraged group ac-
cording to county codes with a high and low rate of
metastasectomy. These two groups were then matched
and analyzed in a paired Cox-regression model.
Thereafter, the entire analysis was repeated in each of
the three groups according to the site of the metastasis
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Ten thousand three hundred twenty-five of 217,068 pa-
tients diagnosed with colorectal cancer between 2010
and 2015 were included (Fig. 1). The median follow-up
time was 15 months (interquartile range: 6 to 28 months)
for all patients and 19months (interquartile range: 8 to
35months) for those alive at the end of follow up. At
the end of follow-up, 4299 (41.6%) patients were alive,
5667 (54.9%) died from cancer and 359 (3.5%) from
other reasons. Overall, 8195 (79.4%) patients had liver
metastases only, 807 (7.8%) patients presented with lung
metastases only and 1323 (12.8%) presented with metas-
tases on both sites (Table 1). Metastasectomy was per-
formed in 2906 (28.1%) patients. The multivariable
Fig. 1 Flow chart of patients’ cohort definition. Data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute in the United States, covering approximately 28% of cancer cases in the United States were used for the present population-based
analysis. Of 217,068 patients diagnosed with colorectal cancer between 2010 and 2015, 10,325 were eligible for analysis at the end of the
selection process
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logistic regression confirmed the significant imbalances
in the baseline characteristics between patients with and
without metastasectomy for the entire risk set except for
the site of the primary, T-stage and ethnicity.
Impact of metastasectomy on survival for all metastatic sites
The median CSS in patients with and without metasta-
sectomy was 2.8 and 1.8 years and the 3-year survival
rates were 46.3% (95% confidence interval (CI): 44.1–
48.7%) and 29.4% (95% CI: 28.1–30.7%, HR = 0.62, 95%
CI: 0.58–0.66, P < 0.001), respectively. The median OS in
patients with and without metastasectomy was 2.6 and
1.7 years and the 3-year survival rates were 44.5% (95%
CI: 42.3–46.8%) and 27.5% (95% CI: 26.2–28.7%, HR =
0.62, 95% CI: 0.58–0.65, P < 0.001), respectively. In
multivariable analysis, metastasectomy was associated
with improved CSS (HR = 0.75, 95% CI: 0.70–0.80, P <
0.001) and OS (HR = 0.75, 95% CI: 0.70–0.80, P < 0.001).
Survival was better when the metastatic site was in the
lung only and worse when occurring on both liver and















Resection No 7419 (71.9%) 7419 (100%) – – 5695 (69.5%) 663 (82.2%) 1061 (80.2%) < 0.001
Yes 2906 (28.1%) – 2906 (100%) 2500 (30.5%) 144 (17.8%) 262 (19.8%)
Metastasis Liver only 8195 (79.4%) 5695 (76.8%) 2500 (86.0%) < 0.001 8195 (100%) – – –
Lung only 807 (7.8%) 663 (8.9%) 144 (5.0%) – 807 (100%) –
Liver and Lung 1323 (12.8%) 1061 (14.3%) 262 (9.0%) – – 1323 (100%)
Tumor localization Right colon 3485 (33.8%) 2602 (35.1%) 883 (30.4%) < 0.001 2808 (34.3%) 220 (27.3%) 457 (34.5%) < 0.001
Transverse 1401 (13.6%) 1005 (13.5%) 396 (13.6%) 1140 (13.9%) 98 (12.1%) 163 (12.3%)
Left colon 3311 (32.1%) 2346 (31.6%) 965 (33.2%) 2666 (32.5%) 231 (28.6%) 414 (31.3%)
Rectosigmoid 966 (9.4%) 680 (9.2%) 286 (9.8%) 736 (9.0%) 88 (10.9%) 142 (10.7%)
Rectum 1162 (11.3%) 786 (10.6%) 376 (12.9%) 845 (10.3%) 170 (21.1%) 147 (11.1%)
T-Stage T1 to T3 6643 (64.3%) 4727 (63.7%) 1916 (65.9%) 0.034 5348 (65.3%) 532 (65.9%) 763 (57.7%) < 0.001
T4 3682 (35.7%) 2692 (36.3%) 990 (34.1%) 2847 (34.7%) 275 (34.1%) 560 (42.3%)
N-Stage N0 2103 (20.4%) 1439 (19.4%) 664 (22.8%) < 0.001 1654 (20.2%) 230 (28.5%) 219 (16.6%) < 0.001
N+ 8222 (79.6%) 5980 (80.6%) 2242 (77.2%) 6541 (79.8%) 577 (71.5%) 1104 (83.4%)
Grade G1/2 7715 (74.7%) 5450 (73.5%) 2265 (77.9%) < 0.001 6090 (74.3%) 615 (76.2%) 1010 (76.3%) 0.118
G3/4 2610 (25.3%) 1969 (26.5%) 641 (22.1%) 2105 (25.7%) 192 (23.8%) 313 (23.7%)
Chemo- and/or No 2842 (27.5%) 2294 (30.9%) 548 (18.9%) < 0.001 2216 (27.0%) 235 (29.1%) 391 (29.6%) 0.437
Radiotherapy Yes 7483 (72.5%) 5125 (69.1%) 2358 (81.1%) 5979 (73.0%) 572 (70.9%) 932 (70.4%)
Year of diagnosis 2010–2012 5304 (51.4%) 3915 (52.8%) 1389 (47.8%) < 0.001 4279 (52.2%) 365 (45.2%) 660 (49.9%) 0.005
2013–2015 5021 (48.6%) 3504 (47.2%) 1517 (52.2%) 3916 (47.8%) 442 (54.8%) 663 (50.1%)
Age (years) < 50 1799 (17.4%) 1130 (15.2%) 669 (23.0%) < 0.001 1474 (18.0%) 120 (14.9%) 205 (15.5%) 0.005
50–64 4065 (39.4%) 2843 (38.3%) 1222 (42.1%) 3241 (39.5%) 285 (35.3%) 539 (40.7%)
65–79 3247 (31.4%) 2448 (33.0%) 799 (27.5%) 2525 (30.8%) 285 (35.3%) 437 (33.0%)
80+ 1214 (11.8%) 998 (13.5%) 216 (7.4%) 955 (11.7%) 117 (14.5%) 142 (10.7%)
Gender Male 5693 (55.1%) 4159 (56.1%) 1534 (52.8%) 0.003 4585 (55.9%) 387 (48.0%) 721 (54.5%) 0.003
Female 4632 (44.9%) 3260 (43.9%) 1372 (47.2%) 3610 (44.1%) 420 (52.0%) 602 (45.5%)
Ethnicity Caucasian 7787 (75.4%) 5576 (75.2%) 2211 (76.1%) 0.336 6237 (76.1%) 591 (73.2%) 959 (72.5%) 0.117
African-American 1555 (15.1%) 1117 (15.1%) 438 (15.1%) 1219 (14.9%) 115 (14.3%) 221 (16.7%)
Other/Unknown 983 (9.5%) 726 (9.8%) 257 (8.8%) 739 (9.0%) 101 (12.5%) 143 (10.8%)
Marital status Married 5583 (54.1%) 3925 (52.9%) 1658 (57.1%) < 0.001 4501 (54.9%) 399 (49.4%) 683 (51.6%) 0.061
Single/Widowed 3057 (29.6%) 2256 (30.4%) 801 (27.6%) 2398 (29.3%) 259 (32.1%) 400 (30.2%)
Other/Unknown 1685 (16.3%) 1238 (16.7%) 447 (15.4%) 1296 (15.8%) 149 (18.5%) 240 (18.1%)
n (percent)
aChi-squared test
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lung data (Table 2). Survival was better in left sided
colonic and rectal cancer, in nodal negative patients
with lower T-stage and lower graded tumors and in
younger, married, Caucasian patients who underwent
chemotherapy (Table 2).
Impact of metastasectomy on survival stratified for the
metastatic sites
Metastasectomy was performed in 2500 of 8195 (30.5%)
patients with exclusively liver metastases, in 144 of 807
(17.8%) patients with exclusively lung metastases and in
262 of 1323 (19.8%) patients with metastases on both
sites. Figure 3 summarizes the impact of metastasectomy
for OS and CSS in stratified analyses performed separ-
ately for the three metastatic site groups.
Resection of liver metastases only
The stratified analysis demonstrated liver being the only
metastatic site, for which metastasectomy was uniformly
Table 2 Prognostic factors for overall and cancer-specific survival
overall survival using Cox regression cancer-specific survival using Cox regression
unadjusteda full modelb unadjusteda full modelb
HR (95% CI) pc HR (95% CI) pc HR (95% CI) pc HR (95% CI) pc
Resection No Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
Yes 0.62 (0.58–0.65) 0.75 (0.70–0.80) 0.62 (0.58–0.66) 0.75 (0.70–0.80)
Metastasis Liver only Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
Lung only 0.78 (0.70–0.86) 0.69 (0.62–0.76) 0.75 (0.68–0.84) 0.67 (0.60–0.75)
Liver and Lung 1.62 (1.51–1.74) 1.58 (1.47–1.69) 1.64 (1.52–1.76) 1.59 (1.48–1.71)
Tumor localization Right Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
Transverse 0.91 (0.84–0.98) 1.01 (0.93–1.09) 0.91 (0.84–0.98) 1.01 (0.93–1.10)
Left 0.61 (0.57–0.65) 0.77 (0.72–0.82) 0.61 (0.57–0.65) 0.77 (0.72–0.82)
Rectosigmoid 0.58 (0.53–0.64) 0.72 (0.66–0.80) 0.58 (0.53–0.64) 0.73 (0.66–0.80)
Rectum 0.46 (0.42–0.50) 0.75 (0.68–0.83) 0.46 (0.41–0.50) 0.75 (0.68–0.83)
T-Stage T1 to T3 Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
T4 1.60 (1.52–1.69) 1.44 (1.37–1.52) 1.74 (1.62–1.87) 1.47 (1.40–1.56)
N-Stage N0 Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
N1 1.64 (1.54–1.76) 1.57 (1.47–1.69) 1.74 (1.62–1.87) 1.65 (1.53–1.78)
Grade G1/2 Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
G3/4 1.73 (1.63–1.82) 1.50 (1.42–1.59) 1.77 (1.67–1.87) 1.53 (1.44–1.62)
Chemo- and/or No Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
Radiotherapy Yes 0.29 (0.27–0.30) 0.34 (0.32–0.36) 0.30 (0.28–0.31) 0.35 (0.33–0.37)
Year of diagnosis 2010–2012 Reference < 0.001 Reference 0.044 Reference < 0.001 Reference 0.052
2013–2015 0.89 (0.84–0.94) 0.94 (0.89–1.00) 0.89 (0.84–0.94) 0.94 (0.89–1.00)
Age (years) < 50 Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
50–64 1.24 (1.14–1.34) 1.12 (1.03–1.21) 1.21 (1.12–1.31) 1.10 (1.01–1.19)
65–79 1.71 (1.58–1.85) 1.35 (1.25–1.47) 1.62 (1.50–1.76) 1.29 (1.19–1.41)
80+ 3.59 (3.28–3.94) 1.96 (1.77–2.17) 3.35 (3.05–3.69) 1.85 (1.67–2.05)
Gender male Reference 0.106 Reference 0.048 Reference 0.034 Reference 0.2227
female 1.04 (0.99–1.10) 0.95 (0.90–1.00) 1.06 (1.00–1.12) 0.97 (0.92–1.02)
Ethnicity Caucasian Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference 0.001
African-American 1.15 (1.08–1.24) 1.11 (1.04–1.20) 1.15 (1.08–1.24) 1.11 (1.03–1.20)
other/unknown 0.91 (0.83–1.00) 0.91 (0.83–0.99) 0.90 (0.82–0.99) 0.89 (0.81–0.98)
Marital status married Reference < 0.001 Reference < 0.001 Reference < 0.001 Reference < 0.001
single 1.46 (1.38–1.55) 1.21 (1.14–1.28) 1.45 (1.36–1.53) 1.20 (1.13–1.28)
other/unknown 1.12 (1.05–1.21) 1.05 (0.98–1.13) 1.09 (1.01–1.17) 1.02 (0.94–1.10)
Hazard ratios (HR) with 95% confidence intervals (CI) of Wald type
aunivariate Cox regression analysis; bmultivariable Cox regression analysis; clikelihood ratio test
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beneficial regarding OS and CSS in unadjusted and all
adjusted analyses (Figs. 2 and 3).
Resection of lung metastases only
For lung as the only metastatic site, metastasectomy was
beneficial only in unadjusted analysis. The median OS in
patients with and without lung metastasectomy was 3.3
and 2.5 years and the 3-year survival rates were 58.0%
(95% CI: 49.1–68.4%) and 40.9% (95% CI: 36.3–46.1%)
(HR = 0.73, 95% CI: 0.56–0.95, P = 0.016). However, after
multivariable adjustment, lung metastasectomy did not
have a significant impact on OS (HR = 0.86, 95% CI:
0.65–1.14, P = 0.280) and CSS (HR = 0.84, 95% CI: 0.62–
1.12, P = 0.232). Furthermore, no benefit on CSS and OS
was found in patients undergoing resection of lung me-
tastases after propensity score- (PS) and inverse prob-
ability weighted- (IPW) adjustment (Figs. 2 and 3).
Resection of combined lung and liver metastases
In patients with both lung and liver metastases, metasta-
sectomy was beneficial only in unadjusted analysis. The
median overall survivals in patients with and without
metastasectomy were 1.5 and 1.2 years. However, none
of the adjusted analyses yielded a survival benefit for pa-
tients undergoing metastasectomy (Figs. 2 and 3).
Discussion
This is the first SEER analysis using IPW and PS to assess
the impact of metastasectomy on survival in colorectal
cancer patients with special focus on liver and/or lung
metastases and with removed primary tumor. The
present analysis provides compelling evidence of a
statistically significant and clinically relevant increase in
OS and CSS for liver resection but not for metastasect-
omy of lung or both sites.
Outcomes of patients with metastatic colorectal cancer
(mCRC) have improved enormously over the last decade.
Indeed, depending on the extent of metastases and the
biology, the median OS of metastatic colorectal cancer
patients can exceed 3 years [27]. There are different
factors, which led to improved outcomes in patients with
metastatic colorectal cancer: first, our knowledge of the
tumor heterogeneity based on molecular profiling has
changed the therapeutic management of these tumors.
Thus, the more individual systemic treatment results in
higher response rates and consecutively higher rates of
surgical metastasectomy. These therapeutic concepts are
well approved in large randomized trials in the first line
as well second line settings [11, 28]. As refractory
patients will be seen more frequently in sequential treat-
ment of mCRC re-challenge concepts have been investi-
gated with promising results [29, 30].
However, the therapeutic concepts of mCRC do not
only contain chemotherapy or antibodies. Resections of
oligometastatic liver and or lung metastasis are commonly
discussed during multidisciplinary tumor boards and up
to 15% of mCRC patients are evaluated for resection. The
surgical management along the current guidelines of
Fig. 2 Forest plot of unadjusted and adjusted survival analysis stratified for metastatic siteAnalysis of survival was performed separately for
patients with liver only, lung only, lung and liver being the metastatic site. The 95% confidence intervals for the hazard ratios were estimated
using the Wald method and the P-values using the likelihood ratio test. The figure depicts the results for OS and CSS in unadjusted, multivariable
adjusted, inverse propensity weight (IPW)-adjusted and exact matching and weighting propensity score adjusted analysis.
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National Comprehensive Cancer Network (NCCN) and
European Society for Medical Oncology (ESMO) is not re-
stricted to one single organ as well no clear definition on
the number of metastasis at liver or lung will restrict such
procedures within a multidisciplinary approach to mCRC
patients [17, 18]. However, good prognostic and predictive
makers to guide this decision are still missing.
The benefit of metastatic resection for these selected
patients led to an improvement of 5-years survival of
20–38% [31–33]. Most available data supporting resection
of liver and or lung metastases are based on small case
series as well retrospective data and reviews [34, 35]. Large
cohort analyses to address the impact of metastasectomy
in relation to OS or CSS are scarse.
To our knowledge this is the first population-based,
propensity score adjusted analysis investigating the prog-
nostic impact of resection of liver and or lung metastases
in mCRC patients. Being aware of the conflicting data and
the challenge to handle relevant bias due to substantial
imbalances between resected versus not resected mCRC
patients, we have intentionally selected the propensity
score matching as a superior and refined statistical
method in addition to commonly used multivariate
analysis.
Based on a large collective from the SEER database of
patients with metastatic colorectal cancer between 2010
and 2015 with resected primary tumor, the present study
provides compelling evidence that the prognosis of pa-
tients with resection of liver metastasis in the overall
population is better after adjusting for a strong bias re-
garding various patient and tumor characteristics by
the use of the propensity score matching. Conversely,
no differences in OS and CSS appeared in the propen-
sity score adjusted population for the patients undergo-
ing resection of lung metastases or both lung and liver
metastases. Thus, we conclude that the overall survival
improvement in mCRC patients after resection of lung
and both lung and liver metastases described in the sci-
entific literature are not real on a population-based
level but caused by differences regarding confounders
that could not be adjusted for in multivariate regression
analysis.
Our results differ from the finding from Boysen et al. [36]
demonstrating a survival benefit of lung metastasectomy
Fig. 3 Unadjusted and PS-adjusted survival analysis stratified for metastatic site. The upper three plots display the survival curves for cancer-
specific survival in unadjusted analysis for patients with liver, lung and both metastasis with and without resection (Panel A to C). The lower three
plots display the survival curves after exact propensity matching (Panel D to F)
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compared to the group of no resection. However, in this
Danish cohort study the benefit for lung metastasectomy
was only found in univariate analyses and non-significant
benefit was seen at their multivariate analysis for lung
metastasectomy, hence selection bias (healthier patients
with less metastatic disease, and better biology get oper-
ated) is inherent. Luo et colleagues [37] demonstrated in
their SEER database analysis that the metastatic site of pa-
tients with mCRC has prognostic impact. Indeed, isolated
liver metastases have a better prognosis compared to me-
tastases at multiple sites. However, the authors did not
analyze the impact on outcomes of resection and survival
of mCRC patients.
In highly selected patients there might be a benefit for
a sequential metastasectomy of liver followed by sys-
temic treatment followed by metastasectomy of the lung.
However, the patient numbers in published analyses are
low and without control group [38–42]. The same trend
of survival benefit was reported for patients with mCRC
after lung resection [43–45]. The limitations of these
studies are the retrospective nature, inclusion of a highly
selective patient cohort and most of them were done at
a highly specialized cancer center and hence lack the
generalizability to other hospitals. Most importantly, no
thorough risk-adjustment was performed with propensity-
score analyses and hence relevant selection bias is an in-
herent shortcoming. This explains the different results
compared to our study, in which we aimed to properly
address and limit selection bias.
Our study has some limitations, most of them by the
lack of information which were not available from the
SEER database. In fact, the SEER database does not pro-
vide any information about the intention or the extend
of metastasectomy. Hence, we can not ascertain if all the
three groups underwent metastasectomy with curative
intention. However, there is some evidence that resec-
tion of lung metastasis in the setting of liver and lung
metastasis in mCRC does not improve the survival [46],
which is in accordance to our findings.
One limitation is the lack of biomarker information re-
garding RAS and rapidly accelerated fibrosarcoma isoform
B (BRAF) mutations as well as microsatellite instability.
Second, no information concerning the choice of systemic
therapy as well the status of conversion rate for resection
of initially unresectable metastasis are available. Third,
information regarding the time-point of resection, type of
surgery as well the resection margin (R0 or R1) was lack-
ing. Fourth, the SEER database does not provide any infor-
mation regarding the diagnosis of pulmonary metastasis.
Hence it is possible, that small pulmonary nodules in
computed tomography (CT) scans were benign. However,
due to the population-based nature of this analysis that re-
flects the real United States population with metastatic
colon cancer, the lack of this information does not impact
our results, albeit limits the extent of interpretation
of our data.
Conclusion
This population-based propensity score adjusted analysis
of mCRC patients with liver and or lung metastases pro-
vides compelling evidence that the resection of liver me-
tastases improves OS and CSS. In contrary, the resection
lung metastases as well as both lung and liver metastases
did not result in increased survival.
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